Video
Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.
Pharmacy Times interviewed Hans Eriksson, MD, PhD, chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine and their potential impact on the future of neuropsychiatric disorder treatments.
During the discussion, Eriksson addressed why there is a need to further progress the current neuropsychiatric disorder treatments available to patients, how a personalized approach to neuropsychiatric disorder treatment would specifically be beneficial, current research efforts in the development of personalized treatments for neuropsychiatric disorders, and what Eriksson’s hopes are for the future of neuropsychiatric disorder treatments and how they’re approached by researchers and physicians.